13FGuru
Sign in with Google Sign in with Discord

NASDAQ · Health Care

Roivant Sciences Ltd. ROIV

Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies.

Sources StockAnalysis company profile stockanalysis.com
Biotechnology: Pharmaceutical Preparations

Company profile

Business mix

  • Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications.
  • The company’s lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases.
  • In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform.
  • Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.

Current key questions

  • Can the company's products, services, or pipeline expand adoption within biotechnology?
  • How do reimbursement, regulation, clinical data, patents, and commercial execution affect growth?
  • Can margins and cash flow improve while funding research, manufacturing, or go-to-market investment?
Holders 3 Current sample portfolio
Public mentions 0 Videos / interviews / letters
Valuation snapshot
PE N/A FCF -3.69% Buyback 4.35%
2026-06-07

Current firm holders

Firm Weight Value Filing period
Viking Global Investors Andreas Halvorsen 0.5% $184.3M 2026-03-31
Baker Bros. Advisors 0.8% $134.8M 2026-03-31
Gotham Asset Management Joel Greenblatt 0.1% $39.2M 2026-03-31

Recent trading changes over the last 4 quarters

Last 1 quarters Last 2 quarters Last 3 quarters Last 4 quarters
Net buyers 2 Last 4 13F filing periods
Net reducers 1 Last 4 13F filing periods
Unchanged holders 0 Share count unchanged
Increase amount $44.1M Estimated from net added shares
Reduction amount $1.1B Estimated from net reduced shares
Net share change / base shares -74.5% -37,770,456 / 50,706,718
Viking Global Investors Andreas Halvorsen 4 filing periods
13F 2025-06-30 Filed 2025-08-14
Major reduction Shares -25.6% 13F value change -$78.4M
13F 2025-09-30 Filed 2025-11-14
Major reduction Shares -31.1% 13F value change -$28.9M
13F 2025-12-31 Filed 2026-02-17
Major reduction Shares -72.7% 13F value change -$217.2M
13F 2026-03-31 Filed 2026-05-15
Minor increase Shares 3.2% 13F value change +$44.5M
Settlement As of 13F 2026-03-31 · Filed 2026-05-15
Base shares 46,013,752 Last 4 periods -39,361,304 (-85.5%) Total shares 6,652,448 Value $184.3M
Gotham Asset Management Joel Greenblatt 1 filing periods
13F 2026-03-31 Filed 2026-05-15
Major increase Shares 53.1% 13F value change +$19.1M
Settlement As of 13F 2026-03-31 · Filed 2026-05-15
Base shares 925,193 Last 4 periods +490,898 (+53.1%) Total shares 1,416,091 Value $39.2M
Baker Bros. Advisors 4 filing periods
13F 2025-06-30 Filed 2025-08-14
Unchanged Shares 0.0% 13F value change $0
13F 2025-09-30 Filed 2025-11-14
Unchanged Shares 0.0% 13F value change $0
13F 2025-12-31 Filed 2026-02-17
Major increase Shares 47.4% 13F value change +$63.5M
13F 2026-03-31 Filed 2026-05-15
Minor reduction Shares -12.4% 13F value change +$14.3M
Settlement As of 13F 2026-03-31 · Filed 2026-05-15
Base shares 3,767,773 Last 4 periods +1,099,950 (+29.2%) Total shares 4,867,723 Value $134.8M

Recent mentions

No public mentions.